Copy to clipboard 
Smith+Nephew reported 1Q26 orthopedic sales of $1 billion, up 7.4% compared to the first quarter of 2025.
The company’s U.S. hip business grew above market for the fourth consecutive quarter driven by adoption of the CATALSTEM system, particularly in competitive accounts.
The CORI robotic system grew well against challenging prior year comps and changing deal mix. Smith+Nephew signed its largest ever multi-CORI deal with a teaching institution in the U.S. during the quarter.
However, U.S. knee performance was weaker than expected as the company made deliberate trade-offs to balance set deployment and efficiency ahead of the launch of its kinematic knee system LANDMARK, which is expected to make the portfolio more competitive as the market moves toward cementless.
“In U.S. knees, as we’ve acknowledged, we’ve got some ways to go to get our product portfolio to where the market is, particularly when it comes to cementless,” said Smith+Nephew CEO Deepak Nath.
The company’s sports medicine franchise grew in the double-digits, driven by Q-FIX KNOTLESS, REGENETEN and AGILI-C. Sports medicine enabling technology grew on the strength of FASTSEAL and services.
Volume-based procurement for certain sports medicine products in China was delayed until the second half of this year, creating strong demand for Smith+Nephew’s products during the quarter.
While that upside will be offset in the second half, the company expects China to be neutral to growth for the full year, which would mark the first time in years that China is a not a major revenue headwind.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 1Q26 | 1Q25 | $ Chg | % Chg |
|---|---|---|---|---|
| Joint Replacement | $428.2 | $415.4 | $12.8 | 3.1% |
| Knees | $244.5 | $244.0 | $0.5 | 0.2% |
| Hips | $161.6 | $150.5 | $11.0 | 7.3% |
| Extremities | $22.1 | $20.9 | $1.3 | 6% |
| Trauma | $139.3 | $133.6 | $5.7 | 4.3% |
| Sports Medicine | $443.5 | $393.5 | $50.0 | 12.7% |
| Enabling Technology | $25.9 | $23.1 | $2.8 | 12% |
| Other | $5.7 | $5.8 | ($0.1) | (1.7%) |
| Total | $1,042.5 | $971.4 | $71.1 | 7.3% |
Orthopedic Sales by Geography
| Region | 1Q26 | 1Q25 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $538.3 | $524.0 | $14.3 | 2.7% |
| OUS | $504.3 | $447.4 | $56.9 | 12.7% |
| EMEA | $286.7 | $260.9 | $25.8 | 9.9% |
| APAC | $93.6 | $80.2 | $13.4 | 16.7% |
| ROW | $124.0 | $106.2 | $17.7 | 16.7% |
| Total | $1,042.5 | $971.4 | $71.1 | 7.3% |
Smith+Nephew reported 1Q26 orthopedic sales of $1 billion, up 7.4% compared to the first quarter of 2025.
The company's U.S. hip business grew above market for the fourth consecutive quarter driven by adoption of the CATALSTEM system, particularly in competitive accounts.
The CORI robotic system grew well against challenging prior year...
Smith+Nephew reported 1Q26 orthopedic sales of $1 billion, up 7.4% compared to the first quarter of 2025.
The company’s U.S. hip business grew above market for the fourth consecutive quarter driven by adoption of the CATALSTEM system, particularly in competitive accounts.
The CORI robotic system grew well against challenging prior year comps and changing deal mix. Smith+Nephew signed its largest ever multi-CORI deal with a teaching institution in the U.S. during the quarter.
However, U.S. knee performance was weaker than expected as the company made deliberate trade-offs to balance set deployment and efficiency ahead of the launch of its kinematic knee system LANDMARK, which is expected to make the portfolio more competitive as the market moves toward cementless.
“In U.S. knees, as we’ve acknowledged, we’ve got some ways to go to get our product portfolio to where the market is, particularly when it comes to cementless,” said Smith+Nephew CEO Deepak Nath.
The company’s sports medicine franchise grew in the double-digits, driven by Q-FIX KNOTLESS, REGENETEN and AGILI-C. Sports medicine enabling technology grew on the strength of FASTSEAL and services.
Volume-based procurement for certain sports medicine products in China was delayed until the second half of this year, creating strong demand for Smith+Nephew’s products during the quarter.
While that upside will be offset in the second half, the company expects China to be neutral to growth for the full year, which would mark the first time in years that China is a not a major revenue headwind.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 1Q26 | 1Q25 | $ Chg | % Chg |
|---|---|---|---|---|
| Joint Replacement | $428.2 | $415.4 | $12.8 | 3.1% |
| Knees | $244.5 | $244.0 | $0.5 | 0.2% |
| Hips | $161.6 | $150.5 | $11.0 | 7.3% |
| Extremities | $22.1 | $20.9 | $1.3 | 6% |
| Trauma | $139.3 | $133.6 | $5.7 | 4.3% |
| Sports Medicine | $443.5 | $393.5 | $50.0 | 12.7% |
| Enabling Technology | $25.9 | $23.1 | $2.8 | 12% |
| Other | $5.7 | $5.8 | ($0.1) | (1.7%) |
| Total | $1,042.5 | $971.4 | $71.1 | 7.3% |
Orthopedic Sales by Geography
| Region | 1Q26 | 1Q25 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $538.3 | $524.0 | $14.3 | 2.7% |
| OUS | $504.3 | $447.4 | $56.9 | 12.7% |
| EMEA | $286.7 | $260.9 | $25.8 | 9.9% |
| APAC | $93.6 | $80.2 | $13.4 | 16.7% |
| ROW | $124.0 | $106.2 | $17.7 | 16.7% |
| Total | $1,042.5 | $971.4 | $71.1 | 7.3% |
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
